Future of Pharma Podcast Now Available

Posted by ISPE Boston
On January 29, 2019

The ISPE Boston Area Chapter is excited to announce the launch of The Future of Pharma podcast for our members. Each episode of The Future of Pharma podcast will treat you to an in-depth conversation between the host, Samir Gondalia, and the thought leaders of the pharmaceutical industry. Get a glimpse of where our industry […]

Learn About Advances In Brain Stimulation for Debilitating Brain Diseases

Posted by ISPE Boston
On January 29, 2019

Join MDG Boston on Wednesday, February 6, 5:30-8:30 PM at Regis College in Weston for “Advances in Brain Stimulation – Understanding and Treating Debilitating Brain Diseases.” Recent breakthroughs in data analytics and AI are allowing new insights and treatments for the common brain disorders of mood, cognitive function and movement. This progress results from researching […]

“Single Use Success” Panelists Share End User Wisdom

Posted by Jack Campion
On January 29, 2019

On January 17, EMD Serono in Billerica was the locus for one of the most enthusiastically received programs of the year. The topic was single use technology, a perennial subject of great interest. The panel discussion format featured four of our colleagues from area operating companies, each with valuable firsthand experience of this still-evolving technology. […]

Ironwood and Cyclerion Name Women to Chair Boards

Posted by ISPE Boston
On January 28, 2019

The separation of Ironwood Pharmaceuticals into two independent, publicly traded companies, Ironwood and Cyclerion Therapeutics, first announced in May 2018, is on track to be completed during the first half of 2019; and both companies have named women to lead their new boards of directors. Julie McHugh will serve as chair of the new Ironwood […]

Ironwood, Cyclerion CEOs Named as Split Moves Forward

Posted by ISPE Boston
On January 28, 2019

The separation of Ironwood Pharmaceuticals into two independent, publicly traded companies, first announced in May 2018, is on track to be completed during the first half of 2019. In early January, Ironwood announced the appointment of the CEOs of the two companies, to become effective at the time of the separation. Industry veteran Mark Mallon […]

Kyn Therapeutics and Celgene to Develop Immuno-oncology Therapies

Posted by ISPE Boston
On January 25, 2019

Kyn Therapeutics, a Boston-based, clinical-stage biotech launched in December 2017 has announced a global strategic collaboration with Celgene to develop novel immuno-oncology therapies. The collaboration unites Kyn’s immuno-oncology expertise and pipeline with Celgene’s capabilities for developing and commercializing medicines in areas of high unmet medical need. It gives Celgene exclusive options to license Kyn’s aryl […]

Obsidian Therapeutics in Deal with Celgene to Develop Novel Cell Therapies

Posted by ISPE Boston
On January 25, 2019

Cambridge-based biotech Obsidian Therapeutics has announced a strategic collaboration with Celgene for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s Destabilizing Domain (DD) technology. Specifically, the collaboration is based on Obsidian’s DD technology for the controlled expression of IL12 and CD40L, two immunomodulatory factors that have the potential to augment the […]

Scholarship Winners Ensure the Future of Pharma

Posted by ISPE Boston
On January 17, 2019

Biotechnology, chemical engineering, microbial systems analysis – these are just of few of the career choices represented by the latest winners of the Joel Goldenberg Memorial Scholarships awarded by the ISPE Boston Area Chapter Scholarship Foundation and made possible by charitable donations from generous individuals and industry stakeholders. In the words of winner Michelle Wang […]

Lilly to Expand Oncology Portfolio with Purchase of Loxo Oncology

Posted by ISPE Boston
On January 17, 2019

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo for $235 per share in cash, or approximately $8.0 billion. Headquartered in Stamford, Connecticut, Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be […]

Gilead Inks Agreements with Scholar Rock and Agenus

Posted by ISPE Boston
On January 10, 2019

In in the space of two days in December, Gilead Sciences of Foster City, California announced agreements with two Massachusetts-based biotechs, the first with Scholar Rock of Cambridge and the second with Agenus of Lexington. Gilead will work with Scholar Rock to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation […]

Page 87 of 117«‹85 868788 89 ›»